These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1940 related articles for article (PubMed ID: 29359507)

  • 1. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
    Sasidharan Nair V; Elkord E
    Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of costimulatory and inhibitory receptors in FoxP3
    Toker A; Ohashi PS
    Adv Cancer Res; 2019; 144():193-261. PubMed ID: 31349899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treg-mediated acquired resistance to immune checkpoint inhibitors.
    Saleh R; Elkord E
    Cancer Lett; 2019 Aug; 457():168-179. PubMed ID: 31078738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of regulatory T cells in cancer immunity.
    Takeuchi Y; Nishikawa H
    Int Immunol; 2016 Aug; 28(8):401-9. PubMed ID: 27160722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies.
    Nishikawa H; Koyama S
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34330764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD8
    Farhood B; Najafi M; Mortezaee K
    J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.
    Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P
    J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy.
    Wang H; Franco F; Ho PC
    Trends Cancer; 2017 Aug; 3(8):583-592. PubMed ID: 28780935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors.
    Pitt JM; Vétizou M; Daillère R; Roberti MP; Yamazaki T; Routy B; Lepage P; Boneca IG; Chamaillard M; Kroemer G; Zitvogel L
    Immunity; 2016 Jun; 44(6):1255-69. PubMed ID: 27332730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treg Fragility: A Prerequisite for Effective Antitumor Immunity?
    Overacre-Delgoffe AE; Vignali DAA
    Cancer Immunol Res; 2018 Aug; 6(8):882-887. PubMed ID: 30068755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation.
    Yaguchi T; Kawakami Y
    Int Immunol; 2016 Aug; 28(8):393-9. PubMed ID: 27401477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New insight into cancer immunotherapy.
    Escribese MM; Barber D
    Allergol Immunopathol (Madr); 2017 Dec; 45 Suppl 1():50-55. PubMed ID: 29108766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoints in Circulating and Tumor-Infiltrating CD4
    Toor SM; Murshed K; Al-Dhaheri M; Khawar M; Abu Nada M; Elkord E
    Front Immunol; 2019; 10():2936. PubMed ID: 31921188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-cell immunoglobulin and ITIM domain in cancer immunotherapy: A focus on tumor-infiltrating regulatory T cells.
    Tian X; Ning Q; Yu J; Tang S
    Mol Immunol; 2022 Jul; 147():62-70. PubMed ID: 35504059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ＜Editors' Choice＞ Meddling with meddlers: curbing regulatory T cells and augmenting antitumor immunity.
    Kochin V; Nishikawa H
    Nagoya J Med Sci; 2019 Feb; 81(1):1-18. PubMed ID: 30962651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induced regulatory T cells in inhibitory microenvironments created by cancer.
    Whiteside TL
    Expert Opin Biol Ther; 2014 Oct; 14(10):1411-25. PubMed ID: 24934899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TIGIT: A Key Inhibitor of the Cancer Immunity Cycle.
    Manieri NA; Chiang EY; Grogan JL
    Trends Immunol; 2017 Jan; 38(1):20-28. PubMed ID: 27793572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FoxP3
    Saleh R; Elkord E
    Cancer Lett; 2020 Oct; 490():174-185. PubMed ID: 32721551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
    Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
    Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
    Kim N; Kim HS
    Front Immunol; 2018; 9():2041. PubMed ID: 30250471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 97.